Ptc Therapeutics, Inc. Earnings

Ptc Therapeutics, Inc.’s revenue jumped 7.23% since last year same period to $211.01Mn in the Q3 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 17.96% jump in its revenue since last 3-months.

Ptc Therapeutics, Inc.’s net profit jumped 114.9% since last year same period to $15.9Mn in the Q3 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 124.51% jump in its net profits since last 3-months.

Ptc Therapeutics, Inc.’s net profit margin jumped 113.9% since last year same period to 7.53% in the Q3 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 120.78% jump in its net profit margins since last 3-months.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.63 - a -144.31% fall from last quarter’s estimates.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.63.

Ptc Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Ptc Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.